Literature DB >> 25755419

The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, India.

Siddapuram Sivaprasad1, Padaki Nagaraja Rao2, Rajesh Gupta2, Kaitha Ashwini1, Duvvuru Nageshwar Reddy2.   

Abstract

BACKGROUND: The single nucleotide polymorphism (SNP) of IL28B gene on chromosome 19, encoding for the interferon (IFN)-λ-3 is strongly associated with treatment response to pegylated-IFN and ribavirin in patients infected with different genotypes of hepatitis C virus (HCV). Difference between ethnicity and treatment response rates suggesting a key role of host genetics. The IL28B polymorphism (rs12979860C/T) shows a marked differential distribution between racial groups. AIM: The present study is aimed to evaluate genotype and allelic frequency of IL28B gene polymorphism (rs12979860C/T) in Andhra Pradesh, India.
METHODS: A total of 220 healthy controls were recruited for the study. The genotyping of SNP rs12979860C/T on IL28B gene was performed by polymerase chain reaction-direct sequencing method. RESULT: The frequency of CC genotype was found to be significantly (59.09%) higher compared to CT (34.09%) and TT (6.81%) genotypes, respectively. The frequency of major allele C is 0.762 whereas minor allele T is 0.238.
CONCLUSION: The higher distribution of genotype 'CC' of SNP, rs12979860C/T of IL28B gene in study subjects is suggestive of better response of HCV patients to standard anti-HCV therapy.

Entities:  

Keywords:  CHC, chronic hepatitis C virus; GWAS, genome-wide association studies; Genotype; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IL, interleukin; IL28B gene; PEG-IFN-α, pegylated-interferon-α; RBC, red blood cells; RBV, ribavirin; SNP, single nucleotide polymorphism; SVR, sustained virological response; WBC, white blood cells; hepatitis C virus; single nucleotide polymorphism

Year:  2012        PMID: 25755419      PMCID: PMC3940249          DOI: 10.1016/S0973-6883(12)60098-X

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  24 in total

Review 1.  Side effects of therapy of hepatitis C and their management.

Authors:  Michael W Fried
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 2.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

4.  Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

Authors:  Tomokazu Kawaoka; C Nelson Hayes; Waka Ohishi; Hidenori Ochi; Toshiro Maekawa; Hiromi Abe; Masataka Tsuge; Fukiko Mitsui; Nobuhiko Hiraga; Michio Imamura; Shoichi Takahashi; Michaki Kubo; Tatsuhiko Tsunoda; Yusuke Nakamura; Hiromitsu Kumada; Kazuaki Chayama
Journal:  J Hepatol       Date:  2010-09-19       Impact factor: 25.083

5.  Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Authors:  Juan A Pineda; Antonio Caruz; Antonio Rivero; Karin Neukam; Irene Salas; Angela Camacho; José C Palomares; José A Mira; Antonio Martínez; Carmen Roldán; Julián de la Torre; Juan Macías
Journal:  Clin Infect Dis       Date:  2010-10-01       Impact factor: 9.079

6.  Treatment responses in Asians and Caucasians with chronic hepatitis C infection.

Authors:  Kenneth-K Yan; Marianne Guirgis; Thuy Dinh; Jacob George; Anouk Dev; Alice Lee; Amany Zekry
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 7.  Treatment predictors of a sustained virologic response in hepatitis B and C.

Authors:  Annika Kau; Johannes Vermehren; Christoph Sarrazin
Journal:  J Hepatol       Date:  2008-07-31       Impact factor: 25.083

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

View more
  7 in total

Review 1.  Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Radha K Dhiman; Shiv K Sarin; Shivaram P Singh; Yogesh K Chawla; Rakesh Aggarwal; Deepak Amarapurkar; Anil Arora; Vinod K Dixit; Ajit Sood; Samir Shah; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Gaurav Pande; Aabha Nagral; Premashis Kar; Abraham Koshy; Amarender S Puri; C E Eapen; Sandeep Thareja
Journal:  J Clin Exp Hepatol       Date:  2015-09-21

2.  Hepatobiliary quiz 11 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-09

Review 3.  Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.

Authors:  Pankaj Puri; Vivek A Saraswat; Radha K Dhiman; Anil C Anand; Subrat K Acharya; Shivaram P Singh; Yogesh K Chawla; Deepak N Amarapurkar; Ajay Kumar; Anil Arora; Vinod K Dixit; Abraham Koshy; Ajit Sood; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Anshu Srivastava; Ashish Kumar; Manav Wadhawan; Amit Goel; Abhai Verma; Gaurav Pandey; Rohan Malik; Swastik Agrawal
Journal:  J Clin Exp Hepatol       Date:  2016-07-02

4.  IFNL4 haplotype, linkage disequilibrium and their influence on virological response to hepatitis C virus infection in Indian population.

Authors:  Neelanjana Roy; Chandreswar Prasad; Anand Kumar; Krishnendu Mondol; Kajal Jain; Renu Yadav; Jyotish Kumar Jha; Neeti Nadda; Subrat Kumar Acharya; Baibaswata Nayak
Journal:  Virusdisease       Date:  2019-07-24

Review 5.  Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Shiv K Sarin; Radha K Dhiman; Rakesh Aggarwal; Shivaram P Singh; Deepak Amarapurkar; Anil Arora; Mohinish Chhabra; Kamal Chetri; Gourdas Choudhuri; Vinod K Dixit; Ajay Duseja; Ajay K Jain; Dharmesh Kapoor; Premashis Kar; Abraham Koshy; Ashish Kumar; Kaushal Madan; Sri P Misra; Mohan V G Prasad; Aabha Nagral; Amarendra S Puri; R Jeyamani; Sanjiv Saigal; Samir Shah; Praveen K Sharma; Ajit Sood; Sandeep Thareja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2014-06-24

6.  Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal.

Authors:  Hans-Tilmann Kinkel; Dibesh Karmacharya; Jivan Shakya; Sulochana Manandhar; Santosh Panthi; Prajwola Karmacharya; Deepika Sitaula; Reenu Thapaliya; Prawachan K C; Apurva Rai; Sameer Dixit
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

7.  Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients.

Authors:  Rushna Firdaus; Aritra Biswas; Kallol Saha; Anirban Mukherjee; Sujit Chaudhuri; Alok Chandra; Asokananda Konar; Provash Chandra Sadhukhan
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.